Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Engelhardt

Showing results (221-230 of 227) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 227 results.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 23

Showing results (221-230 of 227) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 227 results.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 23